These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 24025132

  • 1. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [Abstract] [Full Text] [Related]

  • 2. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [Abstract] [Full Text] [Related]

  • 7. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY, Zhuang LW, Yu YY, Si CW, Li J.
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [Abstract] [Full Text] [Related]

  • 8. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 9. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD, Chen XF, Zhou Y, Chen XP.
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [Abstract] [Full Text] [Related]

  • 11. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
    Luo XD, Chen XP, Chen XF.
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec 20; 25(12):896-901. PubMed ID: 29325289
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z, Zhou F, Zhou Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun 20; 33(6):878-81. PubMed ID: 23803202
    [Abstract] [Full Text] [Related]

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 20; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 14. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Aug 20; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 15. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, Xie Y, Chen C, Chan HL, Zhao M.
    Clin Infect Dis; 2014 Dec 15; 59(12):1714-23. PubMed ID: 25190434
    [Abstract] [Full Text] [Related]

  • 16. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Dec 15; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 17. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG, Lau DT, Schmid P, Perrillo R.
    Am J Gastroenterol; 2007 Dec 15; 102(12):2718-23. PubMed ID: 17662102
    [Abstract] [Full Text] [Related]

  • 18. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 19. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB, Golge N, Akin MS.
    Eur J Gastroenterol Hepatol; 2013 Nov 14; 25(11):1312-6. PubMed ID: 23652913
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD, Chen XP, Chen R, Chen XF, Huang J.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr 14; 24(4):241-5. PubMed ID: 27470620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.